Skip to main content
OPKO Health Inc. logo

OPKO Health Inc. — Investor Relations & Filings

Ticker · OPK ISIN · US68375N1037 LEI · 529900A4S2D4OGOJLL02 TA Human health and social work activities
Open in API
Filings indexed 3,780 across all filing types
Latest filing 2025-04-23 Report Publication Anno…
Country US United States of America
Listing TA OPK

About OPKO Health Inc.

https://www.opko.com

OPKO Health, Inc. is a fully-integrated healthcare company operating in both pharmaceuticals and diagnostics. Its pharmaceutical division develops and commercializes novel therapies for serious diseases. Key marketed products include NGENLA™, a long-acting treatment for pediatric growth hormone deficiency partnered with Pfizer, and RAYALDEE®. The company's research focuses on advancing multispecific therapies for cancers and infectious diseases. Through its subsidiary, BioReference Laboratories, OPKO operates one of the largest full-service clinical reference laboratories in the U.S., providing comprehensive diagnostic testing services to millions of patients annually.

Recent filings

Filing Released Lang Actions
results of annual meeting held on April 23, 2025
Report Publication Announcement Classification · 98% confidence The document explicitly mentions 'Form 8-K' and states, 'Attached hereto is a report on *Form 8-K ����� �����*'. A Form 8-K is a report of unscheduled material events or corporate changes required by the SEC. However, the document itself is very short (1752 characters) and functions as an announcement stating that the actual Form 8-K report is attached (referenced as '20250423Form8K_isa.pdf'). According to Rule 2, if a document is short and announces the publication of a report, it should be classified as a Report Publication Announcement (RPA). Since this is an announcement about the release of a specific filing (Form 8-K), RPA is the most appropriate classification based on the provided definitions and rules.
2025-04-23 English
Health to Report First Quarter 2025 Financial Results on April 30, 2025, a conference callon April 30th beginning at 4:30 p.m. Eastern time
Earnings Release Classification · 98% confidence The document is a press release announcing the date and time for reporting the First Quarter 2025 financial results and hosting a subsequent conference call and webcast. It explicitly states when the results will be reported ('OPKO Health to Report First Quarter 2025 Financial Results on April 30, 2025'). This type of announcement, which precedes the actual detailed financial report (like an IR or 10-K) and focuses on the timing of the release and the associated call, is best classified as an Earnings Release (ER), as it serves as the initial notification of the upcoming results disclosure. It is not the transcript (CT) or the full report itself (IR/10-K). Q1 2025
2025-04-17 English
Health to Report First Quarter 2025 Financial Results on April 30, 2025, a conference callon April 30th beginning at 4:30 p.m. Eastern time
Report Publication Announcement Classification · 98% confidence The document is a very short announcement (1864 characters) from OPKO Health, Inc., filed with the Israel Securities Authority and the Tel Aviv Stock Exchange. The core content states: "OPKO Health to Report First Quarter 2025 Financial Results on April 30, 2025" and explicitly mentions an attached PDF report. This structure—announcing the future release of financial results rather than containing the results themselves—fits the definition of a Report Publication Announcement (RPA). It is not the full Earnings Release (ER) or Interim Report (IR), but the notice *about* the upcoming release.
2025-04-17 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing Classification · 100% confidence The document text contains the header "FORM 4" and explicitly mentions "STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES" filed pursuant to Section 16(a) of the Securities Exchange Act of 1934. It details transactions by reporting persons (directors/officers) involving the company's common stock, including acquisition codes ('A') and prices. Form 4 is the standard SEC filing for reporting insider transactions (directors, officers, 10% owners). This clearly aligns with the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades).
2025-04-14 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Regulatory Filings Classification · 95% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). The content explicitly states it is reporting on an 'Interested party transaction' and attaches a PDF file named '20250414Form4_isa.pdf'. This type of filing, which reports on specific corporate events or transactions (like related-party dealings) rather than comprehensive financial results (10-K, IR) or management changes (MANG), often falls under general regulatory reporting. Since there is no specific category for 'Interested Party Transaction' and it is a regulatory announcement referencing an attached document, it best fits the general 'Regulatory Filings' category (RNS) or potentially a specific transaction type if one were available. Given the options, RNS is the most appropriate fallback for a specific, non-standard regulatory disclosure that isn't a major event like M&A or a dividend announcement. The document length is short (1768 chars) and it announces the attachment of a report, aligning with the RPA/RNS distinction, but RNS is broader for regulatory disclosures.
2025-04-14 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing Classification · 98% confidence The document text explicitly contains the header "FORM 4" and "STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES". Form 4 is the standard SEC filing used to report changes in beneficial ownership of securities by company insiders (directors, officers, or 10% owners) pursuant to Section 16(a) of the Securities Exchange Act of 1934. This filing type is not explicitly listed in the provided definitions, but it is a specific type of insider transaction report. The closest matching category that covers insider trades is 'Director's Dealing' (DIRS), which is defined as 'Report of personal share transactions by company directors and executives (insider trades)'. Since Form 4 is the definitive document for insider transactions, DIRS is the most appropriate classification among the given options.
2025-04-09 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.